-----Original Message-----
From: Davit Sergeenko
To: Nana Kavtaradze , tamar bodokia
, nino mamaladze
Date: Mon, 20 Apr 2015 19:34:30 +0400
Subject: FW: media update
From: Sonia Choi
Date: Mon, 20 Apr 2015 16:17:15 +0100
To: Davit Sergeenko , "Morgan, Juliette
(CDC/CGH/DGHP) (jtm7@cdc.gov)" , "Averhoff, Francisco
(CDC/OID/NCHHSTP) (fma0@cdc.gov)" , Gregg Alton
, Graeme Robertson
,
Enrico Magnanelli
Subject: media update
Dear all
We have been reaching out to media ahead of EASL and took the
opportunity
to
mention to several reporters that there will be an announcement of an
important ³public health project² this week. We have not shared any
information about the project but have received initial interest from
Wall
Street Journal online, Reuters and Bloomberg.
Dear Minister Would it be possible to receive a copy of your press
release
on official letterhead so we can share it with our media contacts at
the
appropriate time? Could you also please advise if there is a set time
when
the release will be distributed tomorrow?
Many thanks,
Sonia
Sonia Choi
Senior Director, Public Affairs EMEA
----------------------------------------------------------------------
---
---
------------------------------------------------------------
Gilead Sciences Europe Ltd€ Registered as a limited company in England
and
Wales € Registered number 05510315
Registered office: South Building € 2 Roundwood Avenue € Stockley
Park €
Uxbridge € UB11 1AF € England
Office: +44 (0)20 8587 2497 Mobile: +44 (0)7748 842890
----------------------------------------------------------------------
---
---
------------------------------------------------------------
DISCLAIMER If you have received this message in error, please contact
the
sender immediately by return e-mail and notify the sender and then
delete
this message (including any attachments) from your system. This
communication and any attachments contain information which is
confidential
and may also be legally privileged. It is for the exclusive use of the
intended recipient(s). If you are not the intended recipient(s) please
note
that any form of disclosure, distribution, copying or use of this
communication or the information in it or in any attachments is
strictly
prohibited and may be unlawful. E-mail communications cannot be
guaranteed
to be secure or error free, as information could be intercepted,
corrupted,
amended, lost, destroyed, arrive late or incomplete, or contain
viruses.
Gilead does not accept liability for any such matters or their
consequences.
Anyone who communicates with Gilead by e-mail is taken to accept the
risks
in doing so. Gilead has taken every reasonable precaution to ensure
that
any
attachment to this e-mail has been swept for viruses. However, Gilead
cannot
accept liability for any damage sustained as a result of viruses and
would
advise that you carry out your own virus checks before opening any
attachment. Gilead Sciences Europe Ltd ; Registered as a limited
company
in
England and Wales ; Registered number 5510315 Registered office: South
Building ; 2 Roundwood Avenue ; Stockley Park ; Uxbridge ; UB11 1AF ;
England